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Bethany A. Austin, MD,* W. H. Wilson Tang, MD,* E. Rene Rodriguez, MD,†
Carmela Tan, MD,† Scott D. Flamm, MD,*‡ David O. Taylor, MD,*
Randall C. Starling, MD, MPH,* Milind Y. Desai, MD*‡
Cleveland, Ohio
O B J E C T I V E S We sought to assess the diagnostic accuracy and incremental prognostic value of
delayed hyper-enhancement cardiac magnetic resonance (DHE-CMR) compared with electrocardio-
graphic and transthoracic echocardiographic (TTE) parameters in such patients.
B A C KG ROUND Utility of DHE-CMR in the diagnosis of patients with suspected cardiac amyloidosis
(CA) has recently been demonstrated, but its incremental prognostic utility is unclear.
METHOD S Forty-seven consecutive patients (mean age 63 years, 70% men, 55% New York Heart
Association functional class II) with suspected CA who underwent electrocardiography (ECG), TTE,
DHE-CMR, and biopsy (38 endomyocardial, 9 extracardiac) were studied. Low voltage on ECG was
deﬁned as S-wave in lead V1 R-wave in lead V5 or V615 mm. TTE parameters, including deceleration
time, E/E= ratio, and diastolic grade were recorded. CMR was considered positive with diffuse DHE of the
subendocardium extending to adjacent myocardium. All-cause mortality was ascertained.
R E S U L T S In the study population, 59% had low voltage on ECG, 30% had abnormal deceleration
time150 ms, 38% had E/E= ratio15, and 47% had advanced (pseudonormal or restrictive) diastology.
The diagnostic accuracy of DHE-CMR in patients undergoing endomyocardial biopsy was as follows:
sensitivity 88%, speciﬁcity 90%, positive predictive value 88%, and negative predictive value 90%. On
multivariable logistic regression testing of the diagnostic ability of various noninvasive imaging
parameters, only DHE-CMR was signiﬁcant (Wald chi-square statistic 9.6, p 0.01). At 1-year post-biopsy,
there were 9 (19%) deaths. On Cox proportional hazards analysis, only positive DHE-CMR was a predictor
of 1-year mortality (Wald chi-square statistic 4.91, p  0.03).
CONC L U S I O N S A characteristic DHE-CMR pattern is more accurate for diagnosis and is a
stronger predictor of 1-year mortality in patients with suspected CA as compared with other
noninvasive parameters. (J Am Coll Cardiol Img 2009;2:1369–77) © 2009 by the American College
of Cardiology Foundation
From the *Heart and Vascular Institute, †Department of Pathology, and the ‡Imaging Institute, Cleveland Clinic, Cleveland,
Ohio. The institution receives modest research support from Siemens Medical Solutions.Manuscript received May 7, 2009; revised manuscript received July 29, 2009, accepted August 10, 2009.
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1370ne of the most robust predictors of mor-
tality in systemic amyloidosis is cardiac
involvement (1). Cardiac amyloidosis
(CA) has a poor, albeit variable, prognosis
2,3); and early recognition could potentially alter
rognosis by prompting initiation of aggressive
edical treatment and evaluation for transplant
andidacy. However, current techniques do not
rovide sufficient diagnostic information to sup-
lant endomyocardial biopsy (EMB) as the gold
See page 1378
tandard, due in large part to relative lack of
ensitivity and inconsistent diagnostic ability of
standard electrocardiographic (ECG) and
echocardiographic (transthoracic echocar-
diography [TTE]) parameters (4–6).
Although multiple attempts using non-
invasive imaging parameters, including
TTE and ECG, have been made with
regard to prognostication, the data are
variable. In patients with systemic amy-
loidosis and suspected cardiac involve-
ment, previous studies have demonstrated
that increased myocardial echogenicity
(7), mitral deceleration time 150 ms (8),
right ventricular dilation (9), left ventric-
ular ejection fraction (LVEF) 45% (10),
left ventricular wall thickness 15 mm
(1), and myocardial performance index
(MPI) (11) are associated with worse out-
comes. However, prognostic importance
of MPI was refuted in a follow-up study
(7). Low ECG voltage has also been
reported to be predictive of decreased
survival (10), as have elevated biomarkers
such as B-type natriuretic peptide and
roponin (12).
With the recent emergence of delayed hyper-
nhancement cardiac magnetic resonance (DHE-
MR), it is possible to precisely detect areas of
yocardial fibrosis/scarring in-vivo with a high
egree of precision. Furthermore, preliminary work
as demonstrated that CMR is very sensitive in
iagnosis of amyloid deposition within the heart
3,13). However, its diagnostic accuracy has not
een compared with other traditional noninvasive
arameters, nor has its prognostic utility been
reviously described. The aims of this study were:
) to compare the diagnostic accuracy of DHE-
MR with traditional noninvasive imaging param-
tic
sy
ion
nceters in patients with suspected CA that underwent tMB; and 2) to assess the prognostic value of
HE-CMR in patients with suspected CA who
nderwent tissue biopsy, including either EMB or
xtracardiac biopsy.
E T H O D S
atient population. This was an observational study
f 84 consecutive patients with suspected restrictive
r infiltrative cardiomyopathy or patients with
nown systemic amyloidosis and suspected to have
ardiac involvement referred for biopsy between
anuary 2005 and August 2008. Of these, 37 were
xcluded because they did not have DHE-CMR as
art of their initial evaluation. Also, patients with
tandard contraindications to CMR (pacemakers,
efibrillators, aneurysmal clips) were not imaged.
eginning in June 2007, following the Food and
rug Administration’s advisory regarding the use of
adolinium in patients with advanced renal failure,
e did not perform DHE-CMR examination in
uch patients. Hence, the final study population
onsisted of 47 patients undergoing multimodality
maging evaluation.
Each patient underwent a comprehensive assess-
ent, typically within a 24- to 48-h period, includ-
ng clinical evaluation, ECG, Doppler TTE,
HE-CMR, and biopsy (38 EMB and 9 extracar-
iac) (Figs. 1 to 3). New York Heart Association
NYHA) functional class was ascertained at the
ime of their clinical evaluation with a cardiologist.
resence or absence of coronary artery disease was
scertained on coronary angiography (if performed)
ithin 1 month of CMR. Significant disease was
efined as 70% stenosis in at least 1 epicardial
oronary vessel. The electronic medical record was
eviewed for clinical and histopathologic data. Glo-
erular filtration rate (GFR) was calculated in each
ndividual using the Modified Diet in Renal Dis-
ases formula: GFR (ml/min/1.73 m2)  186 
serum creatinine) 1.154  (age)0.203  (0.742, if
emale)  (1.210, if African American) (14). All-
ause mortality was determined using Social Secu-
ity Death Index (SSDI) inquiry. This retrospective
tudy was approved by the institutional review
oard with waiver of informed consent.
CG. Standard 12-lead ECG measurements were
ade. Based on previously described criteria by
arroll et al. (6), low voltage was defined as the sum
f the S-wave in lead V1 R-wave in lead V5 or V6
15 mm. We also classified patients based on other
oltage criteria that have been described by Rahman
t al. (4) (5 mm in the limb leads and10 mm inB B R E V I A T I O N S
N D A C R O N YM S
A cardiac amyloidosis
MR cardiac magnetic
esonance
HE-CMR delayed hyper-
nhancement cardiac magne
esonance
CG electrocardiogram
MB endomyocardial biop
V left ventricle
VEF left ventricular eject
raction
PImyocardial performa
ndex
YHA New York Heart
ssociation
SDI Social Security Death
ndex
TE transthoraciche precordial leads).
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1371chocardiography. Clinical TTE was performed us-
ng commercially available HDI 5000 (Philips
edical Systems, N.A., Bothell, Washington) and
cuson Sequoia (Siemens Medical Solutions USA
nc., Malvern, Pennsylvania) machines. Increased
yocardial “speckling” was a subjective visual as-
essment noted only if reported by the original
nterpreters. End-diastolic interventricular septal
nd posterior wall thickness was measured in a
tandard fashion (15). Left atrial size and left
entricular (LV) end-diastolic and -systolic volume
ere also measured, using Simpson’s biplane
ethod. LVEF was measured using Simpson’s
iplane method (15). The mitral inflow velocity
attern was recorded from the apical 4-chamber
Figure 2. Negative Echocardiography and Positive CMR in a Pat
A 56-year-old man who underwent Doppler echocardiography and
gram did not reveal low voltage. Further staining revealed this to b
tral Doppler pattern showing a deceleration time of 200 ms. (B) DH
Figure 1. Positive Echocardiography and CMR in a Patient With
A 64-year-old man who underwent Doppler echocardiography and
biopsy (EMB) that demonstrated cardiac amyloidosis (CA) is shown.
to be transthyretin-type. Patient was alive at 1 year. (A) Transmitral
chamber delayed hyper-enhancement (DHE)-CMR image demonstra
throughout the left ventricle (LV) (arrow). A  anterior; L  left; LA
right ventricle.characteristic diffuse, delayed hyper-enhancement pattern throughout tiew with pulsed-wave Doppler sample volume
ositioned at the tips of mitral leaflets during
iastole. Deceleration time, measured as the dis-
ance from peak of the E-wave in the mitral inflow
iew to the baseline and peak velocities of E and A
aves were measured (in patients in sinus rhythm).
issue Doppler imaging, including mitral annulus
eptal E= velocity, was measured. Grades of diastol-
gy were assigned by an experienced echocardiog-
apher (M.Y.D.) without knowledge of DHE-
MR results based upon multiple standard criteria,
ncluding mitral inflow Doppler pattern, pulmonary
enous inflow Doppler pattern, tissue Doppler data,
eft atrial size, and LVEF. All diastolic data were
cquired over 10 consecutive beats using sweep
With CA
, followed by EMB that demonstrated CA is shown. Electrocardio-
yloid light-type. The patient was dead within 1 year. (A) Transmi-
R image in a 4-chamber orientation demonstrating the
iac magnetic resonance (CMR), followed by endomyocardial
trocardiogram revealed low voltage. Further staining revealed this
pler pattern showing a deceleration time of 120 ms. (B) 4-
the characteristic diffuse, delayed hyper-enhancement pattern
left atrium; P  posterior; R  right; RA  right atrium; RV ient
CMR
e am
E-CMCA
card
Elec
Dop
ting
he LV (arrow). Abbreviations as in Figure 1.
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1372peeds of 50 and 100 cm/s in a standard fashion.
PI was calculated using a previously described
echnique (11,16). All Doppler measurements were
ade over 3 cardiac cycles and averaged. In patients
ith atrial fibrillation, the data were averaged over 5
ardiac cycles. The Doppler measurements were
ade by an independent observer (B.A.A.) without
nowledge of patient outcomes.
MR. The CMR examinations were performed on
.5-T MR Scanners (Siemens Medical Solutions,
rlangen, Germany), either Sonata (40 mT/m
aximum gradient strength, 200-T/m/s maximum
lew rate) or Avanto (45 mT/m maximum gradient
trength, 200-T/m/s maximum slew rate), using
CG gating. Following scout imaging, balanced
teady-state free precession images were acquired:
cho time  1.6 ms, repetition time  3.3 ms, flip
ngle  70°, and slice thickness  6 mm (long-axis
mages), or 8 to 10 mm (contiguous short-axis
mages encompassing the entire LV, from apex to
ase). For patients able to suspend respiration,
reath-hold duration was 10 to 15 s; otherwise,
mages were acquired using 3 signal averages. Sub-
equently, DHE-CMR images were obtained in
he same long- and short-axis orientations as the
bove-described cine images approximately 10 to 20
in after injection of 0.2 mmol/kg of gadolinium
imenglumine (Magnevist, Berlex Imaging,
ayne, New Jersey) using a phase-sensitive inver-
ion recovery spoiled gradient echo sequence (17):
cho time  4 ms, repetition time  8 ms,
nversion time  260 ms, flip angle  30°, band-
idth  140 Hz/pixel, and 23 k-space lines ac-
Figure 3. Positive Echocardiography and Negative CMR in a Pat
A 78-year-old man who underwent Doppler echocardiography and
and ﬁbrosis, is shown. There was no evidence of amyloidosis. Electr
(A) Transmitral Doppler pattern showing a deceleration time of 109
characteristic diffuse, delayed hyper-enhancement pattern. Abbreviauired every other RR-interval. aLVEF was calculated using clinically available
oftware (Argus, Siemens Medical Solutions).
haracteristic appearance for amyloidosis was de-
ned as presence of DHE in a circumferential
attern involving the entire subendocardium, ex-
ending in various degrees into the surrounding
yocardium (Figs. 1 and 2B). For this study, other
atterns, including focal areas of DHE at right
entricular insertion points and patchy DHE in
ypertrophied LV (both suggestive of hypertrophic
ardiomyopathy) or subepicardial DHE (suggestive
f myocarditis) were deemed negative for CA.
lthough the referring physicians were aware of
HE-CMR results at the time of decision making,
he findings were confirmed in a blinded manner by
he corresponding author.
ndomyocardial biopsy. Right ventricular biopsy (3
o 5 samples of myocardium) was performed under
uoroscopic guidance, after obtaining informed
onsent, via the right internal jugular vein. Biopsies
ere immediately fixed in buffered formaldehyde
olution (4%) and embedded in paraffin within 1
ay after fixation. These sections were analyzed
ith standard hematoxylin–eosin and Congo red
taining for visualization of amyloid deposition.
lectron microscopy was performed in those with
egative Congo red staining. Presence of amyloid
ight chain (AL)-type was ascertained either by
taining of the myocardium for antibodies to light
hains or by a positive bone marrow biopsy 
ositive urine/serum protein immunoelectrophore-
is. Similarly, determination of those with positive
iopsies for amyloidosis who had familial type
Without CA
, followed by EMB, which demonstrated myocyte hypertrophy
diogram revealed low voltage. Patient was alive at 1 year.
. (B) DHE-CMR image in a 4-chamber orientation without the
s as in Figure 1.ient
CMR
ocar
msmyloidosis was determined either with staining of
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1373he myocardium for antibodies to transthyretin or
y positive genetic testing for mutant transthyretin
r apolipoprotein A1. Further histopathologic as-
essment to evaluate for hypertrophic cardiomyop-
thy, Fabry’s disease, and inflammatory myocarditis
as performed as deemed necessary by the pathol-
gist. In the 9 patients that did not undergo EMB,
had kidney biopsies, 2 had fat pad biopsies, 1
ectal, 1 liver, 1 muscle, and 1 stomach biopsy.
tatistical analysis. Discrete variables are presented as
ounts and percentages. Continuous data are ex-
Table 1. Baseline Data of the Study Population
Total P
(N
Age (yrs) 62 [51
Male sex 33
New York Heart Association functional class II 26
Brain natriuretic peptide level (pg/ml) 563 [16
Diuretic use 31
Beta-blocker use 27
Glomerular ﬁltration rate (ml/min/1.73 m2) 75 [47
Low voltage on electrocardiogram (Carroll’s criteria) 27
Low voltage on electrocardiogram (Rahman’s criteria) 4
Atrial ﬁbrillation 8
Speckled appearance 4
Left ventricular ejection fraction (%) 55 [47
Interventricular septal thickness (cm) 1.5 [1.1
Posterior wall thickness (cm) 1.4 [1.1
Left ventricular mass (g) 271 [19
Dilated left atrium (20 cm2) 30
Deceleration time (ms) 172 [13
Deceleration time 150 ms 14
E/E= ratio 15 18
Pseudonormal or restrictive diastology 22
Myocardial performance index 0.51 [0.2
Characteristic DHE on CMR 22
Values are n [95% conﬁdence interval] or n (%).
CMR  cardiac magnetic resonance; DHE  delayed hyper-enhancement.
Table 2. Diagnostic Accuracy of Various Noninvasive Imaging Crit
Low Voltage by
Carroll’s ECG Criteria
Abno
Ec
True positive 13
True negative 10
False positive 11
False negative 4
Sensitivity 76%
Speciﬁcity 48%
Positive predictive value 54%
Negative predictive value 71%CA  cardiac amyloidosis; DT  deceleration time; ECG  electrocardiogram; EMBressed as median and interquartile range. Continuous
onparametric variables were compared using the
ann-Whitney test. Categorical variables were ana-
yzed using chi-square test or Fisher exact test. Logis-
ic regression analysis was performed to test the
ssociation between dependent and multiple indepen-
ent variables. For multivariable analysis, only those
ariables with a p value 0.05 on univariable analysis
ere entered into the model. Survival analysis was
erformed using Cox proportional hazards analysis.
he potential predictors tested on univariable analysis
lation
7)
Biopsy-Negative
(n  22)
Biopsy-Positive
(n  25) p Value
5] 58 [49 to 69] 66 [57 to 79] 0.04
) 15 (68%) 18 (70%) 0.8
) 12 (55%) 14 (56%) 0.9
572] 517 [99 to 608] 607 [232 to 555] 0.4
) 11 (50%) 20 (80%) 0.03
) 13 (59%) 14 (56%) 0.8
0] 71 [48 to 95] 75 [46 to 89] 0.5
) 12 (55%) 15 (60%) 0.6
1 (5%) 3 (13%) 0.3
) 4 (18%) 4 (16%) 0.8
0 4 (16%) 0.04
0] 48 [45 to 55] 52 [46 to 60] 0.6
1.9] 1.3 [1.1 to 1.6] 1.7 [1.4 to 2] 0.004
1.6] 1.2 [0.9 to 1.4] 1.6 [1.2 to 1.9] 0.001
351] 232 [171 to 312] 306 [210 to 363] 0.03
) 15 (68%) 15 (60%) 0.7
209] 168 [120 to 205] 176 [147 to 212] 0.6
) 6 (27%) 8 (32%) 0.5
) 8 (36%) 10 (40%) 0.7
) 9 (41%) 13 (50%) 0.5
0.71] 0.46 [0.22 to 0.74] 0.54 [0.40 to 0.70] 0.2
) 3 (14%) 19 (76%) 0.0001
in Patients With Suspected CA That Underwent EMB (n  38)
l DT (<150 ms)
Doppler
ardiography
Combined
ECG-Echocardiography
Criteria
Presence of
DHE-CMR
6 15 15
13 6 19
8 15 2
11 2 2
35% 88% 88%
62% 29% 90%
43% 50% 88%
54% 75% 90%opu
 4
to 7
(70%
(55%
2 to
(66%
(57%
to 9
(59%
(9%)
(17%
(9%)
to 6
to
to
5 to
(64%
7 to
(30%
(38%
(47%
9 to
(47%eria
rma
on
hoc endomyocardial biopsy; other abbreviations as in Table 1.
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1374clinical, ECG, and TTE) have been demonstrated to
e associated with outcomes in previous studies. In
ddition, presence of characteristic DHE on CMR as
potential predictor of survival was also tested. Uni-
ariable chi-square statistics are reported for each
cs of Patients With False Negative and False Positive
R negative,
ld man History of coronary artery bypass grafting,
chronic renal failure. Patient alive at 1
year. Transmural DHE in apex, distal
anteroseptal, and distal inferior walls,
interpreted as an ischemic scar.
ld man History of coronary artery bypass grafting,
aortic valve replacement, and left
ventricular outﬂow tract obstruction.
Patient alive at 1 year. DHE of the
basal anteroseptal, basal inferior, basal
lateral, basal inferolateral, and basal
inferoseptal in a patient with an
asymmetrically thickened septum,
interpreted as hypertrophic
cardiomyopathy.
R positive,
ld man History of chronic kidney disease,
hypertensive heart disease. EMB
negative. Patient alive at 1 year. Diffuse
subendocardial pattern of DHE.
ld man History of coronary artery disease and
myocardial infarction. EMB negative.
Patient alive at 1 year. Diffuse
subendocardial pattern of DHE.
1 and 2.
ession Analysis Testing the Diagnostic Ability of Various
Parameters in Patients With Suspected CA Who
ging
Univariable Multivariable
Wald
Chi-Square
Statistic p Value
Wald
Chi-Square
Statistic p Value
2.23 0.1
CG 0.60 0.4
0 cm2) 0.98 0.3
thickness 8.6 0.003 1.7 0.19
n fraction 0.04 0.8
n
raphy
0.0 0.9
ictive
ler
2.1 0.2
1.9 0.2
1.06 0.3
time 0.002 0.9
e index 1.7 0.2
16 0.001 9.6 0.002a2.ariable. To be potentially considered for multivariable
nalysis, a p value threshold of 0.05 was specified.
umulative mortality rates of patients stratified into
ifferent subgroups (with or without DHE on CMR)
s a function over time were also obtained by the
aplan-Meier method. Data assembly and basic sta-
istical comparisons were performed with JMP Soft-
are version 6.0.2 (SAS Institute Inc., Cary, North
arolina). Advanced statistical analysis was performed
sing Statistica version 6.1 (Statsoft, Tulsa, Okla-
oma). A p value 0.05 was considered significant.
E S U L T S
he baseline clinical characteristics are shown in
able 1. The vast majority of the patients were
ymptomatic at baseline, with 27% in NYHA func-
ional class II, 47% in NYHA functional class III, and
% in NYHA functional class IV. Five patients (3 in
he EMB group) in the population that underwent
HE-CMR had a GFR 30 ml/min/1.73 m2; and
ll were performed prior to 2007. In the study group,
7 patients had a prior coronary angiogram; of which
had significant coronary artery disease (4 had prior
evascularization).
Of the 47 patients, 25 (53%) patients had biopsy-
roven amyloidosis. Of these 25 biopsies, 17 were
MB and 8 were extracardiac biopsies. Of the 21
atients with a negative biopsy in this cohort, 4 had
lycogen-storage disease, 7 had hypertrophic car-
iomyopathy, 9 had nonspecific fibrosis (likely re-
ated to advanced hypertensive heart disease) and 1
ad myocarditis on histopathologic examination.
ne patient had a negative fat pad biopsy.
The baseline characteristics of the current study
opulation also were similar to the patients with
uspected CA in whom EMB (but not CMR) was
erformed (n  37, excluded from final analyses,
ut shown in the Online Appendix).
iagnostic accuracy of various noninvasive imaging
arameters. The baseline imaging characteristics
re demonstrated in Table 1. Biopsy-positive pa-
ients had increased septal thickness and cardiac
ass compared with biopsy-negative patients.
haracteristic DHE-CMR pattern was seen more
requently in biopsy-positive patients compared
ith biopsy-negative patients. In the entire study
opulation, 22 patients had “typical amyloid pat-
ern” DHE, 12 had no DHE, and 13 had some
egree (mostly patchy) DHE. Within the biopsy-
ositive population (n  25), 19 patients had the
haracteristic diffuse pattern, 2 had patchy DHE,Table 3. Characteristi
DHE-CMR Results
False negative: DHE-CM
EMB positive
Patient #1, 77-year-o
Patient #2, 75-year-o
False positive: DHE-CM
EMB negative
Patient #1, 48-year-o
Patient #2, 68-year-oTable 4. Logistic Regr
Noninvasive Imaging
Underwent EMB
Noninvasive Ima
Parameters
Carroll’s criteria on ECG
Rahman’s criteria on E
Dilated left atrium (2
Interventricular septal
Left ventricular ejectio
Speckled appearance o
surface echocardiog
Pseudonormal or restr
physiology on Dopp
echocardiography
E/A ratio
E/E= ratio 15
Abnormal deceleration
(150 ms)
Myocardial performanc
Positive DHE-CMRnd 4 had no DHE on CMR.
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1375Subsequently, we ascertained the diagnostic ac-
uracy of Carroll’s ECG criteria, abnormal deceler-
tion time (150 ms) and DHE-CMR in the
ubset of patients that underwent EMB (n  38).
atients with extracardiac biopsies (n  8) were
xcluded from accuracy analysis. The results are
emonstrated in Table 2. Similarly, the accuracy of
HE-CMR in the subgroup of patients undergo-
ng EMB with GFR30 ml/min/1.73 m2 (n 35)
as as follows: sensitivity 88%, specificity 95%,
ositive predictive value 93%, and negative predictive
alue 90%. Table 3 shows the characteristics of
atients with a false positive or false negative
HE-CMR, as compared with EMB. Univariable
nd multivariable logistic regression analysis testing
he diagnostic utility of various noninvasive imaging
arameters, in patients with suspected CA that
nderwent EMB, is shown in Table 4. The pres-
nce of a characteristic pattern of DHE on CMR
as the strongest noninvasive predictor of EMB-
ositive results (Table 4).
urvival analysis. Survival analysis was performed on
he entire study population of 47 patients. At 1 year
ollowing biopsy, there were 9 (19%) deaths in the
iopsy-positive patients (7 in the DHE-CMR–
ositive and 2 in the DHE-CMR–negative groups,
espectively, p  0.03). Table 5 shows the predic-
ors of 1-year mortality. Presence of DHE on CMR
as the strongest predictor of 1-year mortality.
one of the other predictors achieved significance
nd so were not entered into the multivariable
odel. Figure 4 shows the Kaplan-Meier survival
urve demonstrating significantly worse survival in
atients who have the characteristic pattern of
HE on CMR.
Of the 25 patients with biopsy-proven amyloid-
sis, 15 had primary, AL-type amyloidosis (4 sur-
ivors and 11 nonsurvivors), and 9 (8 survivors and
nonsurvivor) had transthyretin-type amyloidosis.
ne patient had positive Congo red staining, but
o special stains were performed, as was the routine
ractice at our institution prior to 2006 unless
pecifically requested by the clinician, and work-up
ith serum testing, bone marrow biopsy, and im-
unoelectrophoresis did not reveal the specific
myloid type. One patient underwent heart trans-
lantation, whereas the remainder underwent stan-
ard treatment, including chemotherapy.
I S C U S S I O N
e examined the potential of DHE-CMR for
roviding both diagnostic and prognostic informa-
ion in patients with suspected CA. Presence ofHE on CMR was more accurate in predicting
resence of EMB-positive CA as compared with
CG and TTE variables. Additionally, character-
stic DHE on CMR in patients with suspected CA
Figure 4. Kaplan-Meier Survival Analysis Based on Presence
of Delayed-Hyper-Enhancement
Cumulative mortality rates of the entire study population (N  47),
into different subgroups, with or without DHE-CMR, were obtained
Kaplan-Meier method. It demonstrates that patients with characteri
on CMR had signiﬁcantly worse 1-year survival compared with thos
Table 5. Cox Proportional Hazard Analysis of Various Predictors
in the Entire Study Population With Suspected CA Who Underw
DHE-CMR (N  47)
Variable
W
Chi
St
Age 2
Gender 0
Beta-blocker use 2
Diuretic use 0
Brain natriuretic peptide level 0
New York Heart Association functional class 3
Glomerular ﬁltration rate 1
Low voltage on electrocardiogram (Carroll’s criteria) 0
Low voltage on electrocardiogram (Rahman’s criteria) 0
Left atrial size 20 cm2 0
Left ventricular ejection fraction 2
Interventricular septal thickness 1
Cardiac mass 0
E/E= 15 on Doppler echocardiography 0
Deceleration time on Doppler echocardiography 150 ms 2
Myocardial performance index 1
Pseudonormal or restrictive diastology 0
DHE-CMR 4
Abbreviations as in Table 1.stratiﬁed
by the
stic DHE
e with-of 1-Year Mortality
ent
ald
-Square
atistic p Value
.9 0.09
.15 0.7
.61 0.11
.005 0.9
.05 0.8
.3 0.07
.96 0.15
.67 0.4
.82 0.4
.76 0.4
.21 0.2
.7 0.2
.88 0.4
.83 0.3
.5 0.1
.10 0.3
.004 0.9
.91 0.03out. Abbreviations as in Figure 1.
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1376etter predicted 1-year mortality as compared with
CG and TTE parameters. Because all but 1
atient (who underwent cardiac transplantation)
ad standard medical therapy, difference in treat-
ent did not affect prognosis.
Although the presence of a characteristic DHE
attern on CMR is highly accurate in the diagnosis
f CA, there are some potential pitfalls, as follows:
atchy subendocardial DHE early in the disease
rocess can lead to a “false negative” DHE-CMR
nterpretation, or EMB may miss a patchy area (due
o sampling error), resulting in the DHE-CMR
nterpretation being deemed “false positive.” Addi-
ional problems can arise when there are other
omorbid conditions, such as ischemic heart dis-
ase, that may affect DHE patterns on CMR.
ndeed, for the current study, we deliberately kept
he criteria for “positive” DHE-CMR very strin-
ent and classified patchy DHE-CMR patterns as
negative” for the diagnosis of CA.
The diagnostic accuracy in this study compares
avorably with previous reports, including a recent
tudy by Vogelsberg et al. (13). However, that study
id not compare the accuracy of DHE-CMR with
ther standard noninvasive measurements. Maceira
t al. (18) examined the accuracy of DHE-CMR
omplemented by evaluation of subendocardial T1
apping. They found this parameter to be signifi-
antly different in those with CA compared with
ypertensive controls and that it correlated with
ncreased wall thickness and LV mass (18). A
ollow-up study from their group found that abnor-
al T1 mapping was predictive of mortality (19).
hey did not find an association between the
resence of DHE on CMR and mortality. This
ay have been due to difference in patient profile,
s the diagnosis of CA in their cohort was made
lmost exclusively with extracardiac biopsy, as well
s to the binary interpretation of DHE-CMR in
ur investigation. The difference in timing of DHE
cquisitions also might have potentially played a
ole. An ideal study would test the prognostic
bility of both DHE-CMR and T1 kinetics in a
arger amyloid cohort undergoing EMB.
A variety of TTE parameters have been associated
ith prognosis in CA in previous reports (1,7–11). In
hose investigations that looked at a population with
ystemic amyloidosis using extracardiac biopsy, the
CG and TTE variables that were associated with
dverse prognosis may have acted as surrogate markers
or cardiac involvement, which is known to impart
oor prognosis in systemic amyloidosis. Additionally,
urs is intentionally a highly selected cohort of pa- mients who underwent both DHE-CMR and biopsy
s part of their diagnostic evaluation, and there may be
referral bias. Of note, decision making regarding
ending patients for EMB was not based upon pres-
nce or absence of DHE on CMR.
Because of its accuracy in detecting even very small
reas of fibrosis/amyloid deposition, DHE-CMR
olds the promise to facilitate early diagnosis of CA.
owever, the current study was not designed to
nswer that question. A larger cohort of EMB-
ositive patients with quantitative DHE-CMR as-
essment will be needed to reliably identify patterns
onsistent with early cardiac amyloidosis. The poten-
ial next step is to establish clinical care pathways
here DHE-CMR can be appropriately incorporated
n evaluation and management of amyloidosis. Due to
he small and exploratory nature of this analysis, it
ould not be appropriate to recommend that DHE-
MR supplant other noninvasive modalities such as
CG and echocardiography, nor is it a replacement at
his point for a definitive tissue diagnosis. Instead, it
hould be seen as a valuable complementary technique
hat can provide incremental diagnostic and prognos-
ic information.
The obvious next step would include determina-
ion of whether degree of DHE-CMR is associated
ith outcomes. Also, in those patients in whom
esults are somewhat equivocal (i.e., “patchy” sub-
ndocardial DHE), the CMR results may be used
o guide EMB in order to maximize the diagnostic
ield. Indeed, DHE-CMR has been utilized in
ome small studies as a guide to EMB in order to
ncrease the diagnostic yield (12,20). Finally, it
emains to be seen whether CMR could play a role
n further discriminating between different types of
myloid (i.e., AL vs. transthyretin type).
imitations and future outlook. The observational,
ingle-center nature of the study limits the generaliz-
bility of the findings and raises the possibility of a
election bias. The absolute number of patients exam-
ned is not large. This leads to lack of stable results, at
east from a statistical standpoint. In order to conclu-
ively ascertain comparative and additive prognostic
tility of different variables (clinical, echocardio-
raphic, and CMR), we would require a much larger
ample size with a much longer follow-up, perhaps in
multicenter format. Also, we only performed percu-
aneous right (as opposed to left) ventricular biopsy, as
s the standard in most U.S. hospitals. This could have
esulted in potential sampling errors. Although spe-
ific cardiovascular events, including cardiovascular
ortality, were not recorded during follow-up and
ay be considered a limitation, it has been demon-
s
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1377trated previously that all-cause mortality is more
bjective and unbiased than “cardiac mortality”
21,22).
The current data are certainly hypothesis gen-
rating, and follow-up with a larger population is
eeded to conclusively establish the incremental
rognostic value of DHE-CMR. With the
merging knowledge of nephrogenic systemic
brosis, patient selection is further restricted,
articularly in patients with tenuous renal func-
ion (e.g., amyloid patients with renal involve-
ent) (23). The patients in this cohort who under-
ent CMR with a GFR 30 ml/min/1.73 m2
ere evaluated prior to 2007 and the more recent
oncerns over possibility of nephrogenic systemic
brosis. To the best of our knowledge, none haveet al. Right ventricular dilation in Aletras AH. PhaseO N C L U S I O N S
n our evaluation of noninvasive parameters for
oth diagnosis and risk stratification in patients
ith biopsy-positive CA, we found that a charac-
eristic DHE-CMR pattern was both highly accu-
ate for diagnosis and significantly associated with
-year mortality. Further investigation testing
hether quantitative assessment of the disease bur-
en as assessed by DHE-CMR adds incremental
rognostic value is warranted.
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